Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ProStrakan
Galashiels, Scotland, United Kingdomprostrakan.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ProStrakan was a Scotland-based specialty pharmaceutical company engaged in developing and commercializing prescription medicines for unmet medical needs across Europe and the US. It was acquired by Japan’s Kyowa Hakko Kirin Co., Ltd. in 2011. In April 2016, it rebranded as Kyowa Kirin International plc to unify global operations under the parent company's name. The business remains active under this new identity with a focus on launching near-to-market products.
- Therapeutic areas
- Other
- Modalities
- Small moleculesBiologics/therapeutic antibodies (via parent company capabilities)
- Industry
- Biotech
02
Partnerships
Previously collaborated with Novartis (bone) and Amgen (renal), NovaQuest Alliance for US sales force expansion.
Beyond the preview
Go deeper on ProStrakan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProStrakan.